Optimisticc
Opportunity To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer
A Cancer Grand Challenges project funded by Cancer Research UK.
Discover: a year of scientific creativity
Discover is the annual progress magazine from Cancer Grand Challenges showcasing the power of global team science. Celebrating how the teams are coming together, thinking differently and driving progress against some of cancer’s toughest challenges. Our team OPTIMISTICC is featured in the magazine.
About the Program
We are an international team working together to understand the colorectal cancer microbiome: what it is, how it is associated with cancer, and what treatments will affect the microbiome to promote health.
Our objectives are to:
- Map the colorectal cancer microbiome
- Develop microbiome-targeted therapies for colorectal cancer
- Share and disseminate our findings
What’s New
Mr. Barry D Stein received the 2021 Canadian Cancer Research Alliance’s award for Exceptional Leadership in Patient Involvement in Cancer Research.
Barry is the President and CEO of Colorectal Cancer Canada and a patient advocate on our OPTIMISTICC team. He...
Metatranscriptomics (“MTX”) is a powerful method for measuring microbial gene expression
Metatranscriptomics (abbreviated "MTX") is a powerful method for measuring the gene expression (functional activity)...
BRAF mutation changes the characteristics of colorectal cancers in a mouse model
In a recent publication, the Sears lab showed that introduction of the BRAFV600E mutation into mice colonized with...
Our Sponsor
OPTIMISTICC is a Cancer Grand Challenges team funded by Cancer Research UK.
Our Partners
